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Abstract
Background: The efficacy of fluralaner spot-on solution administered once topically against induced infestations
with Rhipicephalus sanguineus was evaluated in dogs over a 12-week post-treatment period.
Methods: Six negative-controlled studies were conducted, involving a total of 112 adult dogs (57 mixed breed, 47
Beagles, eight Labradors). In each study, dogs were randomized to two groups of eight to ten dogs each. On day 0,
dogs in each treated group were topically administered fluralaner spot-on solution once at a dose of 25 mg/kg
body weight, while dogs in each control group were not treated. Two days before treatment, and on days 28, 56
and 84 after treatment, all dogs were infested with approximately 50 unfed, adult Rh. sanguineus ticks (sex ratio 1:1).
Ticks were removed and counted on days 2, 30 (4 weeks), 58 (8 weeks), and 86 (12 weeks) after treatment to assess
efficacy.
Results: Efficacy against ticks 2 days after treatment was 91.1 % (study 1), 98.4 % (study 2), 100 % (study 3), 97.6 %
(study 4), 99.6 % (study 5), and 99.8 % (study 6). At all other assessment time points, tick efficacy was 95.4–100 %.
Tick reduction in all treatment groups was significant at all assessment time points (P < 0.0001).
Conclusions: A single topical administration of fluralaner spot-on solution provides a high level of therapeutic and
persistent efficacy against Rh. sanguineus ticks over the subsequent 12 weeks.
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Background
Rhipicephalus sanguineus, the brown dog tick, is the
most widespread tick worldwide [1]. The domestic dog
is the main host of this tick in both urban and rural
areas [2, 3], but it can also occasionally infest a wide
range of domestic and wild hosts, including cats, rodents,
birds, and humans [4, 5]. Rhipicephalus sanguineus ticks
can attach everywhere on the dog, but the head (particu-
larly the ears), interdigital spaces, back, inguinal region
and axilla are among their preferred attachment sites [6].
In tropical and subtropical areas, this tick is prevalent
throughout the year [6, 7], whereas in temperate regions it
is most active from the late spring to early autumn [7].
Rhipicephalus sanguineus ticks can even overwinter in the
environment and infest dogs during winter in some re-
gions of temperate climate (e.g. southeastern Oklahoma
and northwestern Arkansas, United States) [6]. As known
vectors of pathogen transmission as well as a cause of dis-
comfort and blood loss for dogs, ticks and tick infestations
are a serious concern for owners. Therefore, control of
Rh. sanguineus is of great medical and veterinary
importance.
Over the last decade, the number of products and
strategies available for tick control has increased remark-
ably, offering veterinarians and pet owners the option of
choosing their preferred product [8]. Most of the exist-
ing commercial tick control products usually have a
4 week tick-killing and/or repellent effect via contact ex-
posure of ticks to the treated animal [9]. An alternative
of tick control in dogs is being offered by using drugs
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from the isoxazoline chemical class (i.e. fluralaner [10],
afoxolaner [11] and sarolaner [12]). This alternative
exerts its effect when ticks attach to the host and are
exposed to the drug through feeding activity [10]. By
using fluralaner spot-on solution, a second convenient
route of fluralaner administration besides the oral route
(Bravecto™) is being presented to veterinarians and pet
owners. After topical administration, fluralaner is readily
absorbed from the administration site into the skin, from
where it is distributed systemically throughout the body.
An uptake of the medicated tissue fluid by the Rh. san-
guineus tick results in a potent tick-killing effect. Phar-
macokinetic data suggest that by topical administration
of fluralaner 12 weeks of efficacy against Rh. sanguineus
can be provided [13].
This paper summarizes the results of six independent
studies, which evaluated the efficacy of fluralaner spot-on




Six studies (studies 1–6) were conducted in dogs using
induced tick infestations with Rh. sanguineus after single
topical fluralaner (Bravecto™ Spot-on Solution) adminis-
tration. All studies were in accordance with Good Clinical
Practice (VICH guideline GL9, Good Clinical Practice,
EMA, 2000). Three studies were conducted in South
Africa (studies 1–3) and three studies were conducted in
the United States (studies 4–6). All studies were random-
ized and performed as either negative-controlled and
partly masked (studies 1, 4–6), or open-labelled (studies 2
and 3) (Table 1). Each study was approved by the
corresponding local Ethics Committee responsible for
the respective CRO before study start.
In total, 112 adult dogs (57 mixed breed, 47 Beagles,
eight Labradors), consisting of males and females be-
tween 0.5 and 11 years of age, and weighing between 4.3
and 35.6 kg before treatment, were involved in the
studies. Each dog was in good health, had not been
treated with any parasite control product within 2 to
3 months prior to a 7-day acclimatization period, did
not harbor any ticks before treatment, and was uniquely
identified by a tattoo or a microchip number.
Prior to randomization, dogs were clinically examined
and weighed. The parasite susceptibility of each dog was
confirmed through the infestation with approximately 50
unfed, adult Rh. sanguineus ticks (sex ratio 1:1), followed
by tick removal and count 48 h (± 4 h) later.
All dogs, from every study group, harbored more than
25 % of the number of originally infested ticks. Dogs
were blocked by descending live tick counts and one dog
in each block was randomized to two study groups (one
treatment and one control group) of eight dogs (studies
2 and 3) or ten dogs (studies 1, 4–6), using a computer
generated randomization list.
All dogs were kept indoors and housed individually
during the study course. They were fed a commercially
obtained dry dog food at least once daily at the recom-
mended rate; drinking water was provided ad libitum.
General health observations were performed once daily
throughout the study.
Treatment
On day 0 (i.e. day of treatment), dogs in the treatment
group were treated with fluralaner spot-on solution
(Bravecto™ Spot-on Solution), based on the dog’s individ-
ual body weight, to achieve a dose of 25 mg fluralaner/
kg body weight. Between 0.4 and 3.2 ml of fluralaner
spot-on solution/dog was administered once topically at
one or more spots, depending on the administration vol-
ume, along the dog’s dorsal line. During administration,
the dog was standing, or lying with its back horizontally.
The first spot was administered between the shoulder
blades and the other spots were administered approxi-
mately 5–10 cm caudal of the previous spot. The hair
was parted, the tip of a positive displacement pipette
(studies 2 and 3) or of a disposable syringe (studies 1, 4–6)
Table 1 Study details
Study set-up Study site Animals per group Dog breed Weight (kg) Age (years) Tick isolate
usedStudy number Treatment group Control group
1 ClinVet (South Africa) 10 10 Mixed and Beagles 8.0–20.2 0.9–6 EU
2 Malelane Research Unit,
MSD Animal Health (South Africa)
8 8 Mongrels and Labradors 10.7–35.6 3–6 SA
3 Malelane Research Unit,
MSD Animal Health (South Africa)
8 8 Mongrels and Labradors 11.3–29.9 2–6 SA
4 BerTek, USA 10 10 Mixed 6.8–14.9 2.4–11.3 USA
5 Young Veterinary Research
Services, USA
10 10 Beagles 7.7–16.3 5.5–6.6 USA
6 MPI Research, USA 10 10 Beagles 4.3–8.7 ≥0.5 USA
Abbreviations: EU Europe, SA South Africa, USA United States
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was placed vertically on the skin, and the solution was ad-
ministered directly to the skin by pressing the plunger of
the syringe to empty its contents. After administration,
the dog was held upright for approximately 5 min to ob-
serve the treatment site. No run or drip-off was observed
and no additional treatment solution was applied to any
dog. Dogs in the control group remained untreated.
Tick infestations and assessments
Infestations using laboratory reared Rh. sanguineus ticks
were conducted on sedated dogs (study 1) or non-
sedated dogs (studies 2–6) 2 days before treatment (i.e.
day -2), and on days 28 (4 weeks), 56 (8 weeks), and 84
(12 weeks) after treatment. Dogs in studies 4–6 were not
sedated prior to each infestation, but were placed in an
infestation chamber for approximately 4 h (± 10 min) to
ensure that the ticks had established an infestation. After
the infestation period, the dog was released back to its
kennel. Dogs in studies 1–3 were infested in their
kennel.
The tick isolate used in each study for each infestation
was not older than 10 years and ticks were regularly
added from the field (Table 1). At each infestation time
point, each dog was infested with 50 (± 4) viable, unfed
adult ticks (sex ratio 1:1), applied directly to its fur along
the dorsal rump area, which allowed the ticks to crawl
into the hair coat and select an attachment site.
Tick removal and counts were performed 2 days after
treatment (i.e. on day 2) and then 48 h (± 4 h) after each
infestation (i.e. on days 2, 30, 58 and 86), and were classi-
fied as dead or alive, attached or unattached, and engorged
or unengorged. In studies 1, 4, 5 and 6 personnel conduct-
ing tick classification and tick counting were masked to
the treatment status of each dog.
Efficacy evaluation
The statistical analysis was performed using the software
package SAS® (SAS Institute Inc., Cary, NC, USA, release
9.1.3 (study 2), 9.2 (studies 1 and 3) and 9.3 (studies 4–6).
The individual dog was the experimental unit in all statis-
tical calculations. The percentage efficacy against ticks
was calculated for the treatment group at each assessment
time point using geometric means with Abbott’s formula:
Efficacy (%) = 100 × (MC - MT)/MC, where MC is the
mean number of total live ticks on untreated control
dogs and MT is the mean number of total live ticks on
treated dogs. Log-transformed [ln(x + 1)] counts of live
attached ticks were used to confirm the efficacy calcula-
tion. Significant differences were assessed between the
log-counts of live ticks in the treated group at each as-
sessment time point and the log-counts of the untreated
control group. Study groups were compared using a lin-
ear mixed model, which included study group as a fixed
effect and block as a random effect. The two-sided level
of significance was set P ≤ 0.05.
Results
Two days after a single topical treatment with fluralaner
spot-on solution, efficacy rates of 91.1 % (study 1), 98.4 %
(study 2), 100 % (study 3), 97.6 % (study 4), 99.6 % (study
5), and 99.8 % (study 6) were achieved against Rh. sangui-
neus ticks (i.e. therapeutic efficacy). The persistent efficacy
against Rh. sanguineus ticks, at the assessment time points
30, 56 and 86 in the different studies varied between 95.4
and 100 %. Tick reduction in all treatment groups was sig-
nificant at all assessment time points (P < 0.001) (Table 2).
Adequate tick infestations (at least six animals with a
tick attachment rate > 25 %) were achieved in the con-
trol groups of studies 1, 4, 5 and 6 at all tick assessment
time points. In study 2, at the 30-day assessment time
point (4 weeks after treatment), five out of eight control
dogs were adequately infested (mean attachment rate
33.0 %) and in study 3, at the 2 day assessment time
point, four out of eight control dogs were adequately
infested (mean attachment rate 28.5 %). However, as
these inadequate infestations only occurred on one occa-
sion in each of the two studies and as the mean attach-
ment rate was > 25 %, the control dog tick infestations
were considered to be sufficiently vigorous to provide a
valid result.
All dogs were carefully monitored for adverse events
throughout the 12-week post-treatment observation
period. One dog in study 2 developed slight erythema at
the administration site for 24 h after treatment, and an-
other dog in study 2 had mild wheal development at the
administration site 2 h after treatment. Both dogs recov-
ered fully without concomitant treatment. No other ad-
verse reactions were observed in these dogs or any other
dog in the studies either at the administration site or
systemically throughout the study duration.
Discussion
Fluralaner spot-on solution is the first topically adminis-
tered ectoparasiticide to provide an extended period of
persistent efficacy against ticks and fleas for dogs [14].
Results of the six studies in this paper demonstrate that
fluralaner provides excellent therapeutic and persistent
efficacy against adult Rh. sanguineus ticks over the entire
12-week recommended re-treatment interval following
single topical administration. These results are consistent
with the pharmacokinetic data reported by Kilp et al. [13].
Rh. sanguineus ticks are prevalent in tropical and sub-
tropical regions throughout the entire year and in tem-
perate regions for much of the year [6, 7]. In addition,
these ticks can infest homes and kennels with multiple
life stages of ticks present in the housings. Therefore,
persistent effective control of this tick is of critical
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Table 2 Mean tick counts and efficacy (%) after a single topical fluralaner administration (Bravecto™ spot-on solution) against Rh. sanguineus infestations in dogs
Assessment time points a Study day 2 Study day 30 Study day 58 Study day 86
Study Fluralaner Control Fluralaner Control Fluralaner Control Fluralaner Control
1 Meanb tick counts (n) 1.8 (3.8) 20.5 (25.1) 0 (0) 29.1 (29.8) 0 (0) 32.6 (32.9) 0 (0) 33.8 (34.0)
Count range (n) 0–19 4e–44 0 20–39 0 26–39 0 29–39
Efficacyc (%) 91.1 (84.9) d 100 (100) d 100 (100) d 100 (100) d
P-value 0.0004 < 0.0001 < 0.0001 < 0.0001
2 Meanb tick counts (n) 0 (0) 18.7 (19.9) 0 (0) 13.8 (16.5) 0 (0) 24.7 (26.3) 0.1 (0.1) 34.2 (35.8)
Count range (n) 0 10f–34 0 3f–34 0 16–37 0–1 26–67
Efficacy c (%) 100 (100) d 100 (100) d 100 (100) d 100 (100) d
P-value < 0.0001 < 0.0001 < 0.0001 < 0.0001
3 Meanb tick counts (n) 0 (0) 10.4 (14.3) 0 (0) 24.3 (25.5) 0 (0) 15.7 (17.9) 0 (0) 19.8 (23.3)
Count range (n) 0 4g–37 0 14–38 0 6g–26 0 6g–35
Efficacy c (%) 100 (100) d 100 (100) d 100 (100) d 100 (100) d
P-value < 0.0001 < 0.0001 < 0.0001 < 0.0001
4 Meanb tick counts (n) 0.9 (2.8) 37.4 (38.6) 0 (0) 26.1 (27.7) 0.2 (0.3) 18.1 (19.6) 0.6 (1.1) 19.4 (20.8)
Count range (n) 0–23 24–51 0 16–41 0–2 8h–33 0–5 12h–32
Efficacy c (%) 97.6 (92.7) d 100 (100) d 98.9 (98.5) d 96.7 (94.7) d
P-value < 0.001 < 0.001 < 0.001 < 0.001
5 Meanb tick counts (n) 0.7 (1.8) 21.1 (25.0) 0 (0) 26.4 (26.9) 0 (0) 28.8 (29.8) 0.1 (0.1) 22.3 (23.1)
Count range (n) 0–11 2i–40 0 19–37 0 18–43 1–0 13–33
Efficacy c (%) 96.6 (92.8) d 100 (100) d 100 (100) d 99.7 (99.6) d
P-value ≤ 0.001 ≤ 0.001 ≤ 0.001 ≤ 0.001
6 Meanb tick counts (n) 0.1 (0.1) 30.4 (30.8) 0.1 (0.1) 24.0 (24.5) 0.1 (0.1) 17.6 (18.7) 0.0 (0.0) 17.8 (18.3)
Count range (n) 0–1 21–38 0–1 18–31 0–1 12j–33 0 11j–25
Efficacy c (%) 99.8 (99.7) d 99.7 (99.6) d 99.6 (99.5) d 100 (100) d
P-value < 0.001 < 0.001 < 0.001 < 0.001
aAssessment of ticks 48 h (± 4 h) after treatment or re-infestation following treatment; bGeometric mean (arithmetic mean); cCalculated based on geometric mean (arithmetic mean); dLog-counts of live ticks from the
treatment group were significantly different (P ≤ 0.05) from log-counts of the respective untreated control group
e eight from ten dogs adequately infested; f seven from eight dogs adequately infested (Study day (SD) 2), five from eight dogs adequately infested (SD 30); g four from eight dogs adequately infested (SD 2), six from
eight dogs adequately infested (SD 58), six from eight dogs adequately infested (SD 86); h eight from ten dogs adequately infested (Study day (SD) 58 and SD 86): i nine from ten dogs adequately infested (Study day











importance. Topically administered fluralaner provides
12 weeks of persistent efficacy against Rh. sanguineus
ticks which means that four treatments will deliver tick
protection for approximately 1 year. In comparison,
other drugs of the chemical isoxazoline class only pro-
vide a maximum of 4-week tick control [11, 12]. The
most common cause of treatment failure is reported to
be incorrect treatment administration [15], therefore
minimizing the number of required administrations can
be a factor in reducing the risk of treatment failure.
Topically administered tick repellent treatments may
not provide the same level of efficacy in the extremities
as can be delivered by systemic treatments [16]. There-
fore, topically administration of a systemically active in-
gredient, in this case fluralaner, provides a high level of
efficacy over the entire body surface. As previously
noted, Rh. sanguineus ticks can show attachment predi-
lection for body sites that may not be as effectively pro-
tected following topical administration of a non-systemic
active product. For example, ticks may attach between
the foot pads of dogs on the ventral surface of the foot,
an area that is frequently wet and difficult to protect
with an external (non-systemic treatment [17]. Bravecto™
Spot-on Solution combines convenient administration
with persistent efficacy over 12 weeks post-treatment.
Treatment safety is a concern for veterinarians in clinical
practice. In the six studies there were mild treatment site
dermal reactions observed in two treated dogs that resolved
within two or 24 h without concomitant treatment. There
were no systemic adverse reactions in any of the treated
dogs. Therefore, it is expected that topically administered
fluralaner will deliver the same strong level of systemic
safety observed with orally administered fluralaner [18].
Conclusions
Fluralaner spot-on solution administered once topically
to dogs delivers a very high level of therapeutic and persis-
tent efficacy against Rh. sanguineus ticks over the subse-
quent 12-weeks.
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